President of UOKiK has agreed to taking control by Valeant Pharmaceuticals over Sanitas

Both companies operate in the market of production and sales of medicines used e.g. in dermatology. As a result of the concentration of Valeant Pharmaceuticals of Canada will take control of Lithuania's Sanitas by buying shares representing 87.2 percent of its share capital. Valeant Pharmaceuticals subsidiaries are Polfa Rzeszow and Valeant IPM from Rzeszów, and Emoi-Fars of Ksawerów. Sanitas subsidiaries are Jelfa of Jelenia Gora and Homeofarm of Gdansk.

In accordance with the provisions, the transaction is subject to notification to the antitrust authority, if it involves enterprises whose total turnover in the preceding year exceeded EUR 1 billion globally or EUR 50 million in Poland

After the antitrust proceedings the President of the Authority concluded that the concentration will not significantly reduce competition.

In accordance with the provisions, the transaction is subject to notification to the antitrust authority, if it involves enterprises whose total turnover in the preceding year exceeded EUR 1 billion globally or EUR 50 million in Poland.

We would like to emphasize that the website of the Authority contains information about all antitrust proceedings regarding concentration conducted by the Authority.

Additional information for media:
Małgorzata Cieloch, Spokesperson for UOKiK
Department of International Relations and Communication
Pl. Powstańców Warszawy 1, 00-950 Warszawa
Tel. 22 827 28 92, 55 60 314, 55 60 430
faks 22 826 11 86
E-mail: malgorzata.cieloch@uokik.gov.pl